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Summary.-This report gives the 5-year findings of a double-blind study of long-
term cytotoxic chemotherapy as an adjuvant to surgery in patients receiving busul-
phan or cyclophosphamide for carcinoma of the bronchus compared with a group
receiving a placebo. Of 243 patients initially allocated busulphan, 234 cyclophos-
phamide and249 placebo,28%,27% and34%0 respectively were alive at5 years. There
were significant associations between mortality from bronchial carcinoma and
histological involvement of the resected intrathoracic nodes and the histology of the
tumour.
Haematological toxicity, especially thrombocytopenia, was frequent and severe
in the busulphan series, and low platelet counts continued long after chemotherapy
was stopped.
IN 1964 a Medical Research Council
Wvorking Party planned a study to
evaluate whether long-term cytotoxic
chemotherapy with busulphan or cyclo-
phosphamide, as ani adjuvant to surgery
in the treatment of carcinoma of the
bronchus, could suppress metastases and
prolong survival time, as compared with
placebo. The first report (Medical
Research Council Working Party, 1971)
showed that up to 2 years there was no
evidence that either of the cytotoxic
agents conferred any benefit. There was,
however, a high incidence of hazardous
haematological toxicity with busulphan
and ofside-effects with cyclophosphamide,
mostly gastrointestinal.
All the survivors have now been fol-
lowed up for 5 years and the findings are
reported here.
P"LAN AND) CONDUCT OF THE STUDY
The plan and conduct of the study have
been described in the earlier report (MRC
Working Party, 1971). In brief, after total
resection of the bronchial tumour and
removal of all visible intrathoracic growth,
the patients were allocated at random to
receive tablets of busulphan (the B series),
cyclophosphamide (the C series) or indistin-
guishable placebos (the P series) for 2 years.
For the first 10 days patients received 8
tablets in 1 dose daily (1 tablet of busulphan
was equivalent to 0 5 mg and 1 of cyclo-
phosphamide to 25 mg). Thereafter for main-
tenance chemotherapy they received 6 tablets
daily in the early stages of the study (the
early intake), but due to an unexpectedly
high incidence of toxicity from the cytotoxic
drugs the maintenance dosages w,ere halved
to 3 tablets daily for all 3 regimens (the late
intake). The study was conducted double-
blind throughout the 5-year period, neither
the patient nor the clinician knowing the
agent allocated.
Management ofthepatients.-The patient's
general condition wias reported on by the
physician, monthly during the first 3 years
and 3-monthly thereafter, and a postero-
anterior chest radiograph w%as taken 3-
monthly. The haemoglobin estimation, total
white cell and platelet counts were under-
taken monthly in the first 2 years and
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thereafter only when requested by the
physician.
RESULTS
As there were no important differences
between patients in the early and late
intakes (except in the occurrence of drug
toxicity) the amalgamated results are
presented.
Survival in the 3 series up to 5 years
The survival rates were similar in the
3 series (Table I and Figure). At 6
months 83% of the 243 B patients, 80%
ofthe 234 C and 84% ofthe 249 P patients
were alive, declining to 48%, 48% and
50% at 2 years, and 28%, 27% and 34%
at 5 years. None of the differences
between the series was statistically signifi-
cant.
The proportions certified as dying
from bronchial carcinoma during the 5
years were similar in the 3 series, 144
(59%) of the B, 142 (61°%) of the C and
141 (57%) of the P patients. Patients
certified as dying from other causes were
30 (12%), 29 (12%) and 23 (9%) respec-
tively.
TABLE I.-Survival up to 5 Years
Patients surviving at (months)
6~~~~~~ Total
Treatment series patients
Busulphan (B) 243
Cyclophosphamide (C) 234
Placebo (P) 249
All treatments 726
0/o
83
80
84
82
12
NO. %
157 65
155 66
163 65
475 65
24
No. %
116 48
113 48
124 50
353 49
36
No. %
92 38
86 37
105 42
283 39
48
No. %
80 33
69 29
97 39
246 34
60
No. %
69 28
63 27
85 34
217 30
Busulphan
Cyclophosphamide - - - -
Placebo - -
27%
3
Years
FIG. Survival up to 5 years.
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Condition of the survivors at 5 years
The general condition of the 217
survivors at 5 years was reported as good
in 77%, fair in 21% and poor in 2%;
71 % were at work, or, if retired, were on
full activity, 27% were out and about but
had restricted activity and only 5 (2%)
patients were confined to hospital or
bedridden. There were only minor dif-
ferences between the survivors in the 3
series. Definite metastases were not
reported in a single patient and were
suspected in only 1 (C) patient.
Metastases
(a) Frequency.-During the 5 years,
metastases were reported to be definitely
present at the last examination before
death in 51% of the 144 B, 42% of the
142 C and 50% of the 141 P patients who
died of carcinoma of the bronchus, and
were suspected in another 28%, 32% and
29%, respectively. In contrast, only 2
(1 B, 1 P) of the 83 patients whose death
was certified as due to causes other than
carcinoma of the bronchus had clinically
definite metastases.
(b) Time of detection.-Within the first
six months, 8% of the 243 B, 5% of the
234 C and 6% of the 249 P patients had
been reported as having definite meta-
stases; by 2 years the proportions were
25%, 21% and 25% and by 5 years
31%, 25% and 32%, respectively. Thus,
the metastases appeared with similar
regularity in the 3 series, none of the
differences between the series being statis-
tically significant.
Influence ofpretreatmentfactors on
mortalityfrom bronchial carcinoma
Because the relationship between pre-
treatment factors and deaths certified as
due to bronchial carcinoma were very
similar in the 3 series, the results have
been amalgamated in Table II. When
the factors were analysed individually,
there was evidence of a less favourable
prognosis infemales (P 0.07), inpatients
who had a pneumonectomy (P = 0-025),
inthose withleft-sided tumours (P 0 03)
TABLE II.-Pretreatment Factors Related to
Deaths Certfied due to Bronchial Carcinoma
Pretreatment factor
Sex
Male
Female
Operation
Segmlental resection
Lobectomy
Pneumonectomy
Patients certified
dead from
bronchial carcinoma
Total - ,
patients No. %
670 387 58
56 40 71
12
339
375
Site of tumour (Bronchus)
rMain 18
Rt Upper lobe 151 Middle lobe 28
Lower lobe 139
Main 35
Lt Upper lobe 229
Lower lobe 126
Resected intrathoracic nodes
Involved histologically 336
Not involved
histologically 390
Total patients 726
8
183
236
8
91
14
70
23
142
79
234
193
427
(67)
54
63
(44)
60
50
50
66
62
63
70
49
59
and in those with histological involvement
of their resected intrathoracic nodes
(P < 0.0001). However, a multiple step-
wise regression analysis, undertaken to
explore the inter-relationships of these
factors, indicated that the apparent prog-
nostic association with sex, type of opera-
tion and site of tumour was due to the
influence of the histological involvement
of the intrathoracic nodes. The regres-
sionanalysis, byeliminatingtheinfluenceof
variables on each other, showed prognostic
associations with histological involvement
of the resected intrathoracic nodes
(P < 0-0001) and with histology of the
tumour (epidermoid vs. non-epidermoid,
P = 0*0003) but not with age, sex, type
of operation, site of tumour or treatment
series.
The fatality from bronchial carcinoma
of patients whose resected intrathoracic
nodes were histologically involved (Table
III) was higher for all 4 main tumour
types than for those whose nodes were not
involved, the differences for epidermoid
tumours and adenocarcinoma being highly
169H. SOTT, R. J. STEPHENS, W. FOX AND D. C. ROY
TABLE III.-Histological Type of Tumour according to Involvement of Intrathoracic
Nodes and Deaths Certifed due to Bronchial Carcinoma
Histology of resected intrathoracie ncodles
Involved Not involved
Diedl from Diedl from
Histological type bronchial bionchial Pvrobability-
(WHO Classificatioin carcinoma carcinoma (Involved rs.
1967) Patients No. % Patients No. % niot involve(l)
Epidermoid 226 144 64 292 139 49 0 0004
Large cell 16 13 81 35 20 57 NS
Small cell 57 46 81 26 15 58 0-06
Adenocareinoma 31 29 94 31 17 55 0-0016
Others 6 2 (33) 6 2 (33) NS
Total 336 234 70 390 193 49 0*00001
significant (P- 00004 and 0 0016, respec-
tively). Further, the prognosis for
patients with epidermoid tumours was
more favourable than for those with other
types of tumour; thus 64% with histolo-
gical involvement of their resected nodes
had died ofbronchial carcinoma by 5 years
compared with 810% of the patients with
large cell tumours (P -- 0.25), 81 % with
small cell tumours (P < 0.025) and 9400
with an adenocareinoma (P 0 002).
For those whose nodes were not involved,
4900 with epidermoid tumours had died,
compared with 5700 of those with large
cell tumours, 58% with small cell tumours
and 550 with adenocarcinoma, none of
these differences being statistically signifi-
caint.
Drug toxicity over the 5-year period
(a) Deaths attributable to toxicity.---
There were 5 patients, all in the early
intake in the busulphan series, in whom
there was evidence that chemotherapy
had materially contributed to death;
four have been described in the 1971
report of the MRC Working Party. The
fifth, a male of 59, died in the third year
from pulmonary embolism and severe
anaemia. He received busulphan daily
for 7 months, a total of610 mg; it was then
interrupted because the platelet count had
fallen to 69 x 109/1. After a further 60 mg
of busulphan and 2 interruptions for
low platelet counts it was finally stopped
at 15 monthswhen the countwas 66 x 109/1.
Ttremainedlow, ranging between 55 x 109/1
and 97 x 109/1 until 30 months, when a
pancytopenia developed. The patient
deteriorated despite repeated blood trans-
fusions, and died in the thirty-second
month without clinical evidence of
metastases. A necropsy was not per-
formed.
(b) Haematological toxicity. Abnormal
blood counts were reported on one or more
occasions in 730o of the B compared with
37% of the C and 20% of the P patients
(Table IV). The commonest manifes-
tation on all 3 regimens was thrombo-
cytopenia and the difference between the
B patients and each of the other 2 series
was highly significant (P < 0 0001) for
each of the 4 comparisons. Nineteen
(80%) of the B patients developed a
pancytopenia compared with only 1 ofthe
C and none of the P patients.
An important feature of the thrombo-
cytopenia in the B series was the length
of time for which low platelet counts
continued after the drug had been stopped.
Thus in 15 (90%) the condition continued
for more than 2 years, in 29 (170%) for
1 to 2 years, in 67 (39%) up to 1 year after
the drug was stopped and in 61 (350o) it
stopped at or before the time of termina-
tion of busulphan. However, it was not
unusual for normal counts to occur
sporadically among a series of abnormals.
In contrast, in only 5 C and 2 P patients
did abnormal platelet counts occur after
stopping the tablets and in none did the
condition continue for longer thain 6
months.
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TABLE IX'. Incidence of Marrow Depression in the 5-year Period
Series
Patients with
abnormal blood counts
on one or more occasions
All patients
Thrombocytopenia
(platelet count <100 x 109/1)
Loucopenia
(total white count <3 0x 10911)
Anaemia
(Hb < 9 g/dl)
Pancytopenia
Total patients
llusulphan (B)
No. %
177 73
172 71
55 23
37 15
19 8
243
Analyses (not presented here) show
that neither the total dosage of busulphan
nor the size of the daily dose influenced
the duration for which thrombocytopenia
persisted after stopping treatment.
In view of reports (Karrer, 1972;
Karrer, Pridun and Zwintz, 1973) that
patients who developed leucopenia during
treatment with cyclophosphamide had a
better prognosis than those who did not,
the occurrence of leucopenia during treat-
ment with cyclophosphamide and with
busulphan was related to survival.
Twelve (32%) of 37 patients treated with
cyclophosphamide who developed leuco-
penia were alive at 5 years compared with
51 (26%) of 197 who had no evidence of
leucopenia. The corresponding proportions
for patients treated with busulphan were
20 (36%) of 55 and 49 (26%) of 188
(P 0.2).
DISCUSSION
This investigation has yielded no
evidence that either of the 2 cytotoxic
drugs in the dosage schedules studied
suppressed or delayed the development of
metastases in bronchial carcinoma, or
improved survival in a 5-year period of
observation of patients who had a total
resection of their tumour and all visible
intrathoracic growth and had no detect-
able extrathoracic metastases. There was
also no evidence that either of the cyto-
toxic drugs influenced the survival of any
subgroup of patients, identifiable by age,
sex, histological involvement of resected
intrathoracic nodes or type of tumour.
Cyclophosphamide (C)
No. 0
86 37
49 21
37 16
15 6
1 0
234
Placebo (P)
No. %
49 20
36 14
5
10 4
0
249
This study investigated 2 different
cytotoxic drugs each given alone daily
for a long period, a standard practice in
the chemotherapy of malignant disease
at the time. Since then, however, there
has been some evidence that cytotoxic
chemotherapy is more effective in bron-
chial carcinoma if given intermittently in
high dosage (Bergsagel, 1971; Karrer,
1972) and if combinations of several drugs
are used (Carbone et al., 1970; Alberto,
1973). Most of these reports have con-
cerned patients with limited disease or
who have undergone surgical resection.
Laing et al. (1975) however, have reported
in patients with inoperable carcinoma of
the bronchus that a policy of giving no
immediate treatment gave better survival
rates and quality of remaining life than
single or multiple drug therapy.
There have been varying claims for
cyclophosphamide as an adjuvant to
radical surgery. Dolton (1970) reported
that, given orally for 2 days before and
up to 9 days after resection for carcinoma
of the bronchus in 114 patients, it did not
diminish the incidence of metastases or
prolong survival at 2 years when com-
pared with a previous series treated by
operation only. Brunner, Marthaler and
Muller(1973)found that cyclophosphamide
i.v. in intermittent courses over a period
of 2 years led to a significantly tncreased
recurrence rate and mortality compared
with an untreated control group, but
Green et al. (1969), in a controlled study,
reported improved survival of patients
when the drug was administered i.v. in
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several courses. These studies were of all
cell types but there is some evidence that
cyclophosphamide is more active against
small-cell tumours (Green et al., 1969;
Higgins, 1972; H0st, 1973). This was not
the experience in the present study, nor
in Tattersall and Ryall's investigation
(1975) in patients treated with radio-
therapy plus intermittent combination
chemotherapy, including cyclophos-
phamide.
The patients in the present study were
a selected group because all visible growth
had been removed at operation, and over
half had no histological involvement of
the resected intrathoracic nodes. The
survival of 30% at 5 years is similar to
the survival rates of 25%O to 30%o
frequently reported for bronchial carci-
noma of all histological types in patients
whose growth has been resected (Belcher
and Anderson, 1965; Bignall, Martin and
Smithers, 1967; Higgins et al., 1969;
Pool, 1971).
It is generally held that the best
chance of survival in lung cancer is with a
well-differentiated cell type and when
complete resection of the growth has been
possible. In the patients under study, all
of whom had a radical resection, the cell
type of the tumour was demonstrated
to influence the prognosis only ifthe intra-
thoracic nodes were also histologically
involved, patients with epidermoid
tumours having a better prognosis than
those with small-cell tumours (P < 0 05)
and those with adenocarcinoma
(P < 0 01). In contrast, although patients
with histologically uninvolved nodes had
a significantly better prognosis than those
with involved nodes (P < 0.0001), the
differences in fatality in the various cell
types in this group were small, although
there was a suggestion that patients with
epidermoid tumours fared slightly better.
Several other features previously
reported to be of prognostic importance
such as age (Belcher and Anderson, 1965;
Higgins et al., 1969), sex (Watson and
Schottenfeld, 1968), type of operation
(Bignall et al., 1967; Pool, 1971) and site
of tumour (Higgins and Beebe, 1967) were
examined in the present study. Although
associations were found with sex, type of
operation and site of tumour when each
was analysed individually, these were
shown to be due to the influence of the
other pretreatment features when exam-
ined in a multiple regression analysis,
which established that the only features
influencing prognosis were involvement
of the intrathoracic nodes, and the
histological type of growth, epidermoid
tumours having a more favourable
prognosis.
There was a high incidence ofhazardous
toxicity with busulphan, which was pre-
scribed in a dosage which had been selected
on the basis of experience in chronic
myeloid leukaemia. The drug materially
contributed to death in 5 (70%) of 76
patients in the early intake, and pancyto-
peniawasexceptionallyfrequent, occurring
in 19 (8%) of the 243 patients. A
high proportion of the patients had
busulphan stopped because of thrombo-
cytopenia; many had low platelet counts
for more than 1 year subsequently. In
contrast, haematological abnormalities
were less frequent with cyclophosphamide
and seldom persisted after stopping the
drug. Finally, none of the patients
on busulphan (or cyclophosphamide)
developed radiographic evidence of lung
changes which could be ascribed to the
drug (Stott et al., 1976).
All the surviving patients are still
being followed up to study whether there
is a risk ofleukaemia with either cytotoxic
agent.
The surgeons, physicians and patholo-
gists who collaborated in this study were
listed in the earlier report (MRC Working
Party, 1971). Their cooperation is again
acknowledged and appreciated. We are
particularly grateful to Dr K. F. W.
Hinson for the histological typing of the
tumours according to the World Health
Organization Classification, 1967. Pro-
fessor J. G. Scadding, the Chairman, Dr
J. R. Bignall, the Secretary, and Professor
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D. A. G. Galton, a member ofthe Working
Party (disbanded in December 1972),
made valuable .*suggestions during the
preparation of this paper.
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